心可舒片联合缬沙坦治疗原发性高血压的临床研究

目的探究心可舒片联合缬沙坦胶囊治疗原发性高血压的临床疗效。方法选择2016年5月—2018年6月南通市第一人民医院收治的158例原发性高血压患者,全部原发性高血压患者分为对照组和治疗组,每组各79例。对照组口服缬沙坦胶囊,80mg/次,1次/d。治疗组在对照组基础上口服心可舒片,1.24g/次,3次/d。两组均连续治疗12周。观察两组的临床疗效,比较两组的血压、血脂水平、血清因子水平。结果治疗后,对照组和治疗组的总有效率分别为86.08%、96.20%,两组比较差异有统计学意义(P0.05)。治疗后,两组24 h平均收缩压(24 h mSBP)、24 h平均舒张压(24 h mDBP)均较治疗前显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组24 h mSBP、24 h mDBP明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,治疗组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均显著降低,治疗前后比较差异有统计学意义(P0.05);且治疗组TC、TG、LDL-C水平均明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组单核细胞趋化蛋白-1(MCP-1)、内皮素-1(ET-1)水平均显著下降,一氧化氮(NO)水平显著上升,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组MCP-1、ET-1、NO水平均明显优于对照组,两组比较差异有统计学意义(P0.05)。结论心可舒片联合缬沙坦胶囊治疗原发性高血压具有较好的临床疗效,能改善患者的血压血脂水平,降低炎症反应,促进血管内皮功能的恢复,具有一定的临床推广应用价值。

Clinical study on Xinkeshu Tablets combined with valsartan in treatment of essential hypertension

Objective To explore the clinical effect of Xinkeshu Tablets combined with Valsartan Capsules in treatment of essential hypertension. Methods Patients (158 cases) with essential hypertension in Nantong First People''s Hospital from May 2016 to June 2015 were randomly divided into control and treatment groups, and each group had 79 cases. Patients in the control group were po administered with Valsartan Capsules, 80 mg/time, once daily. Patients in the treatment group were po administered with Xinkeshu Tablets on the basis of the control group, 1.24 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and blood pressure, blood lipid levels, and serum factor levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.08% and 96.20%, respectively, and there was difference between two groups (P<0.05). After treatment, 24 h m SBP and 24 h m DBP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood pressure indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TC, TG, and LDL-C in the treatment group were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood lipid indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of MCP-1 and ET-1 in two groups were significantly decreased, but the levels of NO in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum factor levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xinkeshu Tablets combined with Valsartan Capsules has clinical curative effect in treatment of essential hypertension, can improve blood pressure and blood lipid level, reduce inflammation reaction, and promote the recovery of vascular endothelial function, which has a certain clinical application value.